BioMarin Pharmaceutical Inc. (BMRN) 10-Year Financial Performance & Capital Metrics

BMRN •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

AboutBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.Show more

Revenue $0 -100.0%
EBITDA $0 -100.0%
Net Income $27M -93.7%
EPS (Diluted) 0.14 -93.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE 0.46% -94.3%
ROIC -
Debt/Equity 0.10 -14.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 22.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 2.6% through buybacks

✗Weaknesses

✗Weak 3Y average ROE of 4.0%
✗Profits declining 50.0% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM12.87%

Profit (Net Income) CAGR

10Y-

5Y-49.96%

3Y-42.59%

TTM-18.26%

EPS CAGR

10Y-

5Y-50.11%

3Y-42.85%

TTM-18.18%

ROCE

10Y Avg-1.99%

5Y Avg3.16%

3Y Avg5.64%

Latest-

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Sep 2025
Sales/Revenue+	1.12B	1.31B	1.49B	1.7B	1.86B	1.85B	2.1B	2.42B	2.85B	0
Revenue Growth %	25.5%	17.62%	13.52%	14.27%	9.18%	-0.76%	13.53%	15.42%	17.97%	-100%
Cost of Goods Sold+	209.62M	241.79M	315.26M	359.47M	524.27M	470.51M	503.02M	532.06M	580.24M	0
COGS % of Revenue	18.77%	18.41%	21.14%	21.09%	28.18%	25.48%	24%	21.99%	20.33%	-
Gross Profit+	907.23M	1.07B	1.18B	1.34B	1.34B	1.38B	1.59B	1.89B	2.27B	0
Gross Margin %	81.23%	81.59%	78.86%	78.91%	71.82%	74.52%	76%	78.01%	79.67%	-
Gross Profit Growth %	22.95%	18.15%	9.72%	14.34%	-0.62%	2.96%	15.79%	18.46%	20.48%	-100%
Operating Expenses+	1.71B	1.09B	1.3B	1.45B	1.38B	1.46B	1.43B	1.7B	1.79B	0
OpEx % of Revenue	153.17%	82.71%	87.14%	84.8%	74.16%	78.98%	68.32%	70.33%	62.7%	-
Selling, General & Admin	476.59M	554.34M	604.4M	680.9M	737.7M	759.4M	823.2M	892.4M	1.01B	0
SG&A % of Revenue	42.67%	42.2%	40.53%	39.96%	39.65%	41.13%	39.27%	36.89%	35.35%	-
Research & Development	661.9M	610.75M	696.33M	715.01M	628.12M	628.79M	649.61M	746.77M	747.18M	0
R&D % of Revenue	59.27%	46.49%	46.69%	41.96%	33.76%	34.06%	30.99%	30.87%	26.18%	-
Other Operating Expenses	572.16M	-78.53M	-1.21M	49.13M	13.81M	69.91M	-40.76M	62.22M	33.28M	0
Operating Income+	-803.43M	-14.7M	-123.52M	-100.46M	-43.44M	-82.34M	160.97M	185.77M	484.21M	0
Operating Margin %	-71.94%	-1.12%	-8.28%	-5.9%	-2.33%	-4.46%	7.68%	7.68%	16.97%	-
Operating Income Growth %	-625.76%	98.17%	-740.3%	18.67%	56.76%	-89.55%	295.5%	15.41%	160.65%	-100%
EBITDA+	-706.52M	73.16M	-27.85M	4.84M	61.73M	25.7M	262.94M	290.16M	580.64M	0
EBITDA Margin %	-63.26%	5.57%	-1.87%	0.28%	3.32%	1.39%	12.54%	11.99%	20.35%	-
EBITDA Growth %	-1012.36%	110.36%	-138.07%	117.39%	1174.66%	-58.37%	923.2%	10.35%	100.11%	-100%
D&A (Non-Cash Add-back)	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M	0
EBIT	-794.92M	3.11M	-99.04M	-73.38M	-21.52M	-60.61M	163.39M	202.39M	554.1M	0
Net Interest Income+	-32.01M	-27.85M	-20.83M	-712K	-12.7M	-4.86M	2.06M	41M	62.15M	0
Interest Income	7.49M	14.85M	22.83M	22.75M	16.61M	10.48M	18.03M	58.34M	74.88M	0
Interest Expense	39.5M	42.71M	43.66M	23.46M	29.31M	15.34M	15.97M	17.34M	12.67M	0
Other Income/Expense	-27.62M	-21.18M	-19.18M	5.65M	-5.56M	6.99M	-11.4M	2.79M	57.55M	0
Pretax Income+	-831.05M	-35.88M	-142.71M	-94.81M	-49M	-75.35M	149.58M	188.56M	541.76M	26.79M
Pretax Margin %	-74.41%	-2.73%	-9.57%	-5.56%	-2.63%	-4.08%	7.14%	7.79%	18.98%	-
Income Tax+	-200.84M	81.17M	-65.49M	-70.96M	-903.03M	-11.27M	8.02M	20.92M	114.9M	0
Effective Tax Rate %	75.83%	326.25%	54.11%	25.15%	-1743.02%	85.04%	94.64%	88.91%	78.79%	100%
Net Income+	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M	26.79M
Net Margin %	-56.43%	-8.91%	-5.18%	-1.4%	45.9%	-3.47%	6.75%	6.93%	14.96%	-
Net Income Growth %	-266.83%	81.43%	34.03%	69.11%	3681.13%	-107.5%	320.91%	18.43%	154.62%	-93.73%
Net Income (Continuing)	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.79	-0.67	-0.44	-0.13	4.53	-0.35	0.75	0.88	2.21	0.14
EPS Growth %	-254.21%	82.32%	34.33%	70.45%	3584.62%	-107.73%	314.29%	17.33%	151.14%	-93.67%
EPS (Basic)	-3.80	-0.67	-0.44	-0.13	4.75	-0.35	0.76	0.89	2.25	0.14
Diluted Shares Outstanding	166.22M	174.43M	177.27M	179.04M	191.68M	182.85M	188.96M	191.59M	196.71M	191.64M
Basic Shares Outstanding	165.99M	174.43M	177.06M	179.04M	180.8M	182.85M	185.27M	187.83M	190.03M	191.64M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Sep 2025
Total Current Assets+	1.42B	2.21B	2.06B	1.94B	2.34B	2.27B	2.75B	2.96B	3.23B	3.95B
Cash & Short-Term Investments	789.68M	1.4B	1.08B	753.81M	1.07B	1.01B	1.29B	1.07B	1.14B	1.56B
Cash Only	408.33M	598.03M	493.98M	437.45M	649.16M	587.28M	724.53M	755.13M	942.84M	1.31B
Short-Term Investments	381.35M	797.94M	590.33M	316.36M	416.23M	426.6M	567.01M	318.68M	194.86M	248.93M
Accounts Receivable	215.28M	261.37M	342.63M	377.4M	448.35M	373.4M	461.32M	633.7M	660.53M	908.21M
Days Sales Outstanding	70.36	72.62	83.86	80.84	87.96	73.82	80.33	95.61	84.48	-
Inventory	355.13M	475.77M	530.87M	680.27M	698.55M	776.67M	894.08M	1.11B	1.23B	1.3B
Days Inventory Outstanding	618.36	718.23	614.62	690.75	486.33	602.5	648.76	759.54	775.41	-
Other Current Assets	61.71M	74.04M	98.4M	130.66M	129.93M	110.44M	104.52M	141.39M	201.53M	185.78M
Total Non-Current Assets+	2.6B	2.43B	2.37B	2.75B	3.51B	3.73B	3.62B	3.89B	3.76B	3.64B
Property, Plant & Equipment	798.77M	896.7M	948.68M	1.01B	1.03B	1.04B	1.07B	1.07B	1.04B	952.51M
Fixed Asset Turnover	1.40x	1.46x	1.57x	1.69x	1.80x	1.78x	1.95x	2.27x	2.74x	-
Goodwill	197.04M	197.04M	197.04M	197.04M	196.2M	196.2M	196.2M	196.2M	196.2M	196.2M
Intangible Assets	553.78M	517.51M	491.81M	456.58M	417.27M	388.65M	338.57M	294.7M	255.28M	213.84M
Long-Term Investments	572.71M	385.79M	235.86M	411.98M	285.47M	507.79M	333.83M	611.13M	521.24M	492.24M
Other Non-Current Assets	32.81M	29.85M	36.57M	122.01M	142.24M	152.12M	176.24M	171.54M	251.39M	277.05M
Total Assets+	4.02B	4.63B	4.43B	4.69B	5.85B	6B	6.38B	6.84B	6.99B	7.59B
Asset Turnover	0.28x	0.28x	0.34x	0.36x	0.32x	0.31x	0.33x	0.35x	0.41x	-
Asset Growth %	7.89%	15.15%	-4.45%	5.94%	24.69%	2.68%	6.17%	7.32%	2.15%	8.66%
Total Current Liabilities+	439.31M	816.52M	523.24M	932.5M	492.55M	546.5M	588.88M	1.18B	606.99M	759.03M
Accounts Payable	191.35M	166.62M	207.62M	240.98M	191.43M	199.68M	231.24M	315.51M	235.4M	0
Days Payables Outstanding	333.19	251.52	240.37	244.69	133.27	154.9	167.79	216.44	148.08	-
Short-Term Debt	22.48M	360.95M	0	361.88M	0	0	0	493.88M	23.07M	0
Deferred Revenue (Current)	0	0	1.47M	13.04M	152K	6.96M	711K	4.62M	1.37M	0
Other Current Liabilities	160.57M	208.89M	240.07M	202.91M	182.82M	258.94M	236.1M	234.92M	132.06M	759.03M
Current Ratio	3.24x	2.70x	3.93x	2.08x	4.76x	4.16x	4.67x	2.51x	5.33x	5.21x
Quick Ratio	2.43x	2.12x	2.92x	1.35x	3.34x	2.74x	3.15x	1.57x	3.29x	3.50x
Cash Conversion Cycle	355.52	539.33	458.11	526.9	441.02	521.42	561.3	638.71	711.8	-
Total Non-Current Liabilities+	818.11M	1.01B	935.95M	635.15M	1.25B	1.19B	1.18B	713.03M	723.96M	747.99M
Long-Term Debt	660.76M	813.52M	830.42M	486.24M	1.08B	1.08B	1.08B	593.1M	595.14M	597.18M
Capital Lease Obligations	0	0	0	0	0	0	0	0	31.26M	0
Deferred Tax Liabilities	0	44.32M	62.07M	0	0	0	0	0	0	0
Other Non-Current Liabilities	157.34M	194.42M	105.53M	148.92M	174.32M	113.53M	100.02M	119.94M	97.57M	150.82M
Total Liabilities	1.26B	1.82B	1.46B	1.57B	1.74B	1.74B	1.77B	1.89B	1.33B	1.51B
Total Debt+	683.24M	1.17B	830.42M	858.82M	1.09B	1.09B	1.09B	1.1B	649.47M	597.18M
Net Debt	274.91M	576.44M	336.44M	421.37M	437.74M	502.26M	368.86M	340.62M	-293.38M	-714.5M
Debt / Equity	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x	0.10x
Debt / EBITDA	-	16.05x	-	177.33x	17.61x	42.40x	4.16x	3.78x	1.12x	-
Net Debt / EBITDA	-	7.88x	-	87.01x	7.09x	19.54x	1.40x	1.17x	-0.51x	-
Interest Coverage	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x	-
Total Equity+	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B	6.09B
Equity Growth %	15.22%	1.53%	5.67%	5.2%	31.5%	3.89%	7.91%	7.57%	14.27%	7.58%
Book Value per Share	16.64	16.10	16.74	17.44	21.42	23.33	24.36	25.84	28.76	31.76
Total Shareholders' Equity	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B	6.09B
Common Stock	173K	176K	178K	180K	182K	184K	186K	189K	191K	-10.32M
Retained Earnings	-1.52B	-1.64B	-1.69B	-1.72B	-861.61M	-930.76M	-789.2M	-621.55M	-194.69M	154.21M
Treasury Stock	-14.32M	-14.22M	-13.3M	-9.96M	-9.84M	0	0	0	0	0
Accumulated OCI	12.82M	-22.96M	5.27M	20.16M	-16.14M	14.43M	-3.87M	-28.79M	61.65M	-13.47M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Sep 2025
Cash from Operations+	-227.84M	-8.76M	20.21M	48.26M	85.36M	304.54M	175.9M	159.26M	572.84M	827.99M
Operating CF Margin %	-20.4%	-0.67%	1.36%	2.83%	4.59%	16.49%	8.39%	6.58%	20.07%	-
Operating CF Growth %	-2.77%	96.16%	330.76%	138.83%	76.88%	256.75%	-42.24%	-9.46%	259.69%	44.54%
Net Income	-630.21M	-117.04M	-77.21M	-23.85M	859.1M	-64.08M	141.56M	167.65M	426.86M	348.9M
Depreciation & Amortization	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M	79.56M
Stock-Based Compensation	134.64M	140.26M	148.82M	159.87M	189.71M	197.26M	196.31M	207.1M	201.57M	181.41M
Deferred Taxes	-228.05M	44.46M	-68.38M	-82.76M	-888.91M	-15.61M	-52.09M	-44.98M	56.1M	48.74M
Other Non-Cash Items	559.15M	-70.34M	-29.27M	-9.2M	44.71M	12.89M	-115.47M	61.65M	8.29M	278.07M
Working Capital Changes	-160.28M	-93.96M	-49.42M	-101.09M	-224.42M	66.03M	-96.38M	-336.54M	-216.4M	-108.68M
Change in Receivables	-51.48M	-25.26M	-54.27M	-37.85M	-59.03M	65.57M	-82.03M	-190.44M	-57.91M	-228.05M
Change in Inventory	-64.51M	-96.89M	-23.75M	-107.55M	-61.15M	-35.06M	-68.26M	-157.06M	-63.53M	119.21M
Change in Payables	-33.89M	24.83M	20.62M	77.09M	-68.71M	15.69M	59.02M	68.85M	-32.24M	66.14M
Cash from Investing+	-484.05M	-305.46M	264.35M	-31.03M	-53.62M	-366.31M	-20.03M	-111.24M	136.49M	-414.24M
Capital Expenditures	-148.38M	-199.22M	-144.62M	-163.41M	-137.52M	-95.58M	-131.54M	-107.61M	-85.42M	-103.04M
CapEx % of Revenue	13.29%	15.17%	9.7%	9.59%	7.39%	5.18%	6.28%	4.45%	2.99%	-
Acquisitions	-2.79M	125M	50M	0	-23.21M	0	0	0	0	-285.19M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-698K	-1.75M	-10K	24.19M	89.64M	-24.64M	103.33M	0	-853K	-7.94M
Cash from Financing+	727.11M	507.14M	-388.01M	-74.67M	181.12M	-48K	-18.65M	-18.73M	-526.45M	-42.39M
Debt Issued (Net)	0	481.69M	-374.95M	-5.09M	203.84M	-3.04M	-2.6M	-2.29M	-494.99M	0
Equity Issued (Net)	1000K	0	0	1000K	-1000K	0	1000K	1000K	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-33.51M	-35.92M	0	-50M	0	0	0	0	0
Other Financing	14.17M	25.46M	-13.05M	-101.2M	27.27M	2.99M	-85.38M	-85.79M	-31.46M	-42.39M
Net Change in Cash	11.29M	189.7M	-104.05M	-56.54M	211.71M	-61.88M	137.25M	30.6M	187.72M	368.84M
Free Cash Flow+	-376.22M	-207.98M	-124.41M	-96.76M	-52.15M	185.31M	54.94M	62.57M	475.42M	724.96M
FCF Margin %	-33.69%	-15.83%	-8.34%	-5.68%	-2.8%	10.04%	2.62%	2.59%	16.66%	-
FCF Growth %	16.27%	44.72%	40.18%	22.22%	46.1%	455.31%	-70.35%	13.88%	659.85%	52.49%
FCF per Share	-2.26	-1.19	-0.70	-0.54	-0.27	1.01	0.29	0.33	2.42	3.78
FCF Conversion (FCF/Net Income)	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x	30.91x
Interest Paid	8.64M	8.54M	11.62M	0	12.18M	10.39M	0	0	10.36M	0
Taxes Paid	95.86M	23.89M	16.68M	0	8.98M	18.15M	0	0	57.27M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-24.39%	-4.2%	-2.67%	-0.78%	23.63%	-1.53%	3.19%	3.51%	8.05%	0.46%
Return on Invested Capital (ROIC)	-21.12%	-0.34%	-2.77%	-2.2%	-0.81%	-1.33%	2.48%	2.71%	6.82%	-
Gross Margin	81.23%	81.59%	78.86%	78.91%	71.82%	74.52%	76%	78.01%	79.67%	-
Net Margin	-56.43%	-8.91%	-5.18%	-1.4%	45.9%	-3.47%	6.75%	6.93%	14.96%	-
Debt / Equity	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x	0.10x
Interest Coverage	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x	-
FCF Conversion	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x	30.91x
Revenue Growth	25.5%	17.62%	13.52%	14.27%	9.18%	-0.76%	13.53%	15.42%	17.97%	-100%

US Stock Screener

...

BioMarin Pharmaceutical Inc. (BMRN) 10-Year Financial Performance & Capital Metrics

BMRN •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

Revenue $0 -100.0%
EBITDA $0 -100.0%
Net Income $27M -93.7%
EPS (Diluted) 0.14 -93.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE 0.46% -94.3%
ROIC -
Debt/Equity 0.10 -14.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 22.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 2.6% through buybacks

✗Weaknesses

✗Weak 3Y average ROE of 4.0%
✗Profits declining 50.0% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM12.87%

Profit (Net Income) CAGR

10Y-

5Y-49.96%

3Y-42.59%

TTM-18.26%

EPS CAGR

10Y-

5Y-50.11%

3Y-42.85%

TTM-18.18%

ROCE

10Y Avg-1.99%

5Y Avg3.16%

3Y Avg5.64%

Latest-

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Sep 2025
Sales/Revenue+	1.12B	1.31B	1.49B	1.7B	1.86B	1.85B	2.1B	2.42B	2.85B	0
Revenue Growth %	25.5%	17.62%	13.52%	14.27%	9.18%	-0.76%	13.53%	15.42%	17.97%	-100%
Cost of Goods Sold+	209.62M	241.79M	315.26M	359.47M	524.27M	470.51M	503.02M	532.06M	580.24M	0
COGS % of Revenue	18.77%	18.41%	21.14%	21.09%	28.18%	25.48%	24%	21.99%	20.33%	-
Gross Profit+	907.23M	1.07B	1.18B	1.34B	1.34B	1.38B	1.59B	1.89B	2.27B	0
Gross Margin %	81.23%	81.59%	78.86%	78.91%	71.82%	74.52%	76%	78.01%	79.67%	-
Gross Profit Growth %	22.95%	18.15%	9.72%	14.34%	-0.62%	2.96%	15.79%	18.46%	20.48%	-100%
Operating Expenses+	1.71B	1.09B	1.3B	1.45B	1.38B	1.46B	1.43B	1.7B	1.79B	0
OpEx % of Revenue	153.17%	82.71%	87.14%	84.8%	74.16%	78.98%	68.32%	70.33%	62.7%	-
Selling, General & Admin	476.59M	554.34M	604.4M	680.9M	737.7M	759.4M	823.2M	892.4M	1.01B	0
SG&A % of Revenue	42.67%	42.2%	40.53%	39.96%	39.65%	41.13%	39.27%	36.89%	35.35%	-
Research & Development	661.9M	610.75M	696.33M	715.01M	628.12M	628.79M	649.61M	746.77M	747.18M	0
R&D % of Revenue	59.27%	46.49%	46.69%	41.96%	33.76%	34.06%	30.99%	30.87%	26.18%	-
Other Operating Expenses	572.16M	-78.53M	-1.21M	49.13M	13.81M	69.91M	-40.76M	62.22M	33.28M	0
Operating Income+	-803.43M	-14.7M	-123.52M	-100.46M	-43.44M	-82.34M	160.97M	185.77M	484.21M	0
Operating Margin %	-71.94%	-1.12%	-8.28%	-5.9%	-2.33%	-4.46%	7.68%	7.68%	16.97%	-
Operating Income Growth %	-625.76%	98.17%	-740.3%	18.67%	56.76%	-89.55%	295.5%	15.41%	160.65%	-100%
EBITDA+	-706.52M	73.16M	-27.85M	4.84M	61.73M	25.7M	262.94M	290.16M	580.64M	0
EBITDA Margin %	-63.26%	5.57%	-1.87%	0.28%	3.32%	1.39%	12.54%	11.99%	20.35%	-
EBITDA Growth %	-1012.36%	110.36%	-138.07%	117.39%	1174.66%	-58.37%	923.2%	10.35%	100.11%	-100%
D&A (Non-Cash Add-back)	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M	0
EBIT	-794.92M	3.11M	-99.04M	-73.38M	-21.52M	-60.61M	163.39M	202.39M	554.1M	0
Net Interest Income+	-32.01M	-27.85M	-20.83M	-712K	-12.7M	-4.86M	2.06M	41M	62.15M	0
Interest Income	7.49M	14.85M	22.83M	22.75M	16.61M	10.48M	18.03M	58.34M	74.88M	0
Interest Expense	39.5M	42.71M	43.66M	23.46M	29.31M	15.34M	15.97M	17.34M	12.67M	0
Other Income/Expense	-27.62M	-21.18M	-19.18M	5.65M	-5.56M	6.99M	-11.4M	2.79M	57.55M	0
Pretax Income+	-831.05M	-35.88M	-142.71M	-94.81M	-49M	-75.35M	149.58M	188.56M	541.76M	26.79M
Pretax Margin %	-74.41%	-2.73%	-9.57%	-5.56%	-2.63%	-4.08%	7.14%	7.79%	18.98%	-
Income Tax+	-200.84M	81.17M	-65.49M	-70.96M	-903.03M	-11.27M	8.02M	20.92M	114.9M	0
Effective Tax Rate %	75.83%	326.25%	54.11%	25.15%	-1743.02%	85.04%	94.64%	88.91%	78.79%	100%
Net Income+	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M	26.79M
Net Margin %	-56.43%	-8.91%	-5.18%	-1.4%	45.9%	-3.47%	6.75%	6.93%	14.96%	-
Net Income Growth %	-266.83%	81.43%	34.03%	69.11%	3681.13%	-107.5%	320.91%	18.43%	154.62%	-93.73%
Net Income (Continuing)	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.79	-0.67	-0.44	-0.13	4.53	-0.35	0.75	0.88	2.21	0.14
EPS Growth %	-254.21%	82.32%	34.33%	70.45%	3584.62%	-107.73%	314.29%	17.33%	151.14%	-93.67%
EPS (Basic)	-3.80	-0.67	-0.44	-0.13	4.75	-0.35	0.76	0.89	2.25	0.14
Diluted Shares Outstanding	166.22M	174.43M	177.27M	179.04M	191.68M	182.85M	188.96M	191.59M	196.71M	191.64M
Basic Shares Outstanding	165.99M	174.43M	177.06M	179.04M	180.8M	182.85M	185.27M	187.83M	190.03M	191.64M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Sep 2025
Total Current Assets+	1.42B	2.21B	2.06B	1.94B	2.34B	2.27B	2.75B	2.96B	3.23B	3.95B
Cash & Short-Term Investments	789.68M	1.4B	1.08B	753.81M	1.07B	1.01B	1.29B	1.07B	1.14B	1.56B
Cash Only	408.33M	598.03M	493.98M	437.45M	649.16M	587.28M	724.53M	755.13M	942.84M	1.31B
Short-Term Investments	381.35M	797.94M	590.33M	316.36M	416.23M	426.6M	567.01M	318.68M	194.86M	248.93M
Accounts Receivable	215.28M	261.37M	342.63M	377.4M	448.35M	373.4M	461.32M	633.7M	660.53M	908.21M
Days Sales Outstanding	70.36	72.62	83.86	80.84	87.96	73.82	80.33	95.61	84.48	-
Inventory	355.13M	475.77M	530.87M	680.27M	698.55M	776.67M	894.08M	1.11B	1.23B	1.3B
Days Inventory Outstanding	618.36	718.23	614.62	690.75	486.33	602.5	648.76	759.54	775.41	-
Other Current Assets	61.71M	74.04M	98.4M	130.66M	129.93M	110.44M	104.52M	141.39M	201.53M	185.78M
Total Non-Current Assets+	2.6B	2.43B	2.37B	2.75B	3.51B	3.73B	3.62B	3.89B	3.76B	3.64B
Property, Plant & Equipment	798.77M	896.7M	948.68M	1.01B	1.03B	1.04B	1.07B	1.07B	1.04B	952.51M
Fixed Asset Turnover	1.40x	1.46x	1.57x	1.69x	1.80x	1.78x	1.95x	2.27x	2.74x	-
Goodwill	197.04M	197.04M	197.04M	197.04M	196.2M	196.2M	196.2M	196.2M	196.2M	196.2M
Intangible Assets	553.78M	517.51M	491.81M	456.58M	417.27M	388.65M	338.57M	294.7M	255.28M	213.84M
Long-Term Investments	572.71M	385.79M	235.86M	411.98M	285.47M	507.79M	333.83M	611.13M	521.24M	492.24M
Other Non-Current Assets	32.81M	29.85M	36.57M	122.01M	142.24M	152.12M	176.24M	171.54M	251.39M	277.05M
Total Assets+	4.02B	4.63B	4.43B	4.69B	5.85B	6B	6.38B	6.84B	6.99B	7.59B
Asset Turnover	0.28x	0.28x	0.34x	0.36x	0.32x	0.31x	0.33x	0.35x	0.41x	-
Asset Growth %	7.89%	15.15%	-4.45%	5.94%	24.69%	2.68%	6.17%	7.32%	2.15%	8.66%
Total Current Liabilities+	439.31M	816.52M	523.24M	932.5M	492.55M	546.5M	588.88M	1.18B	606.99M	759.03M
Accounts Payable	191.35M	166.62M	207.62M	240.98M	191.43M	199.68M	231.24M	315.51M	235.4M	0
Days Payables Outstanding	333.19	251.52	240.37	244.69	133.27	154.9	167.79	216.44	148.08	-
Short-Term Debt	22.48M	360.95M	0	361.88M	0	0	0	493.88M	23.07M	0
Deferred Revenue (Current)	0	0	1.47M	13.04M	152K	6.96M	711K	4.62M	1.37M	0
Other Current Liabilities	160.57M	208.89M	240.07M	202.91M	182.82M	258.94M	236.1M	234.92M	132.06M	759.03M
Current Ratio	3.24x	2.70x	3.93x	2.08x	4.76x	4.16x	4.67x	2.51x	5.33x	5.21x
Quick Ratio	2.43x	2.12x	2.92x	1.35x	3.34x	2.74x	3.15x	1.57x	3.29x	3.50x
Cash Conversion Cycle	355.52	539.33	458.11	526.9	441.02	521.42	561.3	638.71	711.8	-
Total Non-Current Liabilities+	818.11M	1.01B	935.95M	635.15M	1.25B	1.19B	1.18B	713.03M	723.96M	747.99M
Long-Term Debt	660.76M	813.52M	830.42M	486.24M	1.08B	1.08B	1.08B	593.1M	595.14M	597.18M
Capital Lease Obligations	0	0	0	0	0	0	0	0	31.26M	0
Deferred Tax Liabilities	0	44.32M	62.07M	0	0	0	0	0	0	0
Other Non-Current Liabilities	157.34M	194.42M	105.53M	148.92M	174.32M	113.53M	100.02M	119.94M	97.57M	150.82M
Total Liabilities	1.26B	1.82B	1.46B	1.57B	1.74B	1.74B	1.77B	1.89B	1.33B	1.51B
Total Debt+	683.24M	1.17B	830.42M	858.82M	1.09B	1.09B	1.09B	1.1B	649.47M	597.18M
Net Debt	274.91M	576.44M	336.44M	421.37M	437.74M	502.26M	368.86M	340.62M	-293.38M	-714.5M
Debt / Equity	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x	0.10x
Debt / EBITDA	-	16.05x	-	177.33x	17.61x	42.40x	4.16x	3.78x	1.12x	-
Net Debt / EBITDA	-	7.88x	-	87.01x	7.09x	19.54x	1.40x	1.17x	-0.51x	-
Interest Coverage	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x	-
Total Equity+	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B	6.09B
Equity Growth %	15.22%	1.53%	5.67%	5.2%	31.5%	3.89%	7.91%	7.57%	14.27%	7.58%
Book Value per Share	16.64	16.10	16.74	17.44	21.42	23.33	24.36	25.84	28.76	31.76
Total Shareholders' Equity	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B	6.09B
Common Stock	173K	176K	178K	180K	182K	184K	186K	189K	191K	-10.32M
Retained Earnings	-1.52B	-1.64B	-1.69B	-1.72B	-861.61M	-930.76M	-789.2M	-621.55M	-194.69M	154.21M
Treasury Stock	-14.32M	-14.22M	-13.3M	-9.96M	-9.84M	0	0	0	0	0
Accumulated OCI	12.82M	-22.96M	5.27M	20.16M	-16.14M	14.43M	-3.87M	-28.79M	61.65M	-13.47M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Sep 2025
Cash from Operations+	-227.84M	-8.76M	20.21M	48.26M	85.36M	304.54M	175.9M	159.26M	572.84M	827.99M
Operating CF Margin %	-20.4%	-0.67%	1.36%	2.83%	4.59%	16.49%	8.39%	6.58%	20.07%	-
Operating CF Growth %	-2.77%	96.16%	330.76%	138.83%	76.88%	256.75%	-42.24%	-9.46%	259.69%	44.54%
Net Income	-630.21M	-117.04M	-77.21M	-23.85M	859.1M	-64.08M	141.56M	167.65M	426.86M	348.9M
Depreciation & Amortization	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M	79.56M
Stock-Based Compensation	134.64M	140.26M	148.82M	159.87M	189.71M	197.26M	196.31M	207.1M	201.57M	181.41M
Deferred Taxes	-228.05M	44.46M	-68.38M	-82.76M	-888.91M	-15.61M	-52.09M	-44.98M	56.1M	48.74M
Other Non-Cash Items	559.15M	-70.34M	-29.27M	-9.2M	44.71M	12.89M	-115.47M	61.65M	8.29M	278.07M
Working Capital Changes	-160.28M	-93.96M	-49.42M	-101.09M	-224.42M	66.03M	-96.38M	-336.54M	-216.4M	-108.68M
Change in Receivables	-51.48M	-25.26M	-54.27M	-37.85M	-59.03M	65.57M	-82.03M	-190.44M	-57.91M	-228.05M
Change in Inventory	-64.51M	-96.89M	-23.75M	-107.55M	-61.15M	-35.06M	-68.26M	-157.06M	-63.53M	119.21M
Change in Payables	-33.89M	24.83M	20.62M	77.09M	-68.71M	15.69M	59.02M	68.85M	-32.24M	66.14M
Cash from Investing+	-484.05M	-305.46M	264.35M	-31.03M	-53.62M	-366.31M	-20.03M	-111.24M	136.49M	-414.24M
Capital Expenditures	-148.38M	-199.22M	-144.62M	-163.41M	-137.52M	-95.58M	-131.54M	-107.61M	-85.42M	-103.04M
CapEx % of Revenue	13.29%	15.17%	9.7%	9.59%	7.39%	5.18%	6.28%	4.45%	2.99%	-
Acquisitions	-2.79M	125M	50M	0	-23.21M	0	0	0	0	-285.19M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-698K	-1.75M	-10K	24.19M	89.64M	-24.64M	103.33M	0	-853K	-7.94M
Cash from Financing+	727.11M	507.14M	-388.01M	-74.67M	181.12M	-48K	-18.65M	-18.73M	-526.45M	-42.39M
Debt Issued (Net)	0	481.69M	-374.95M	-5.09M	203.84M	-3.04M	-2.6M	-2.29M	-494.99M	0
Equity Issued (Net)	1000K	0	0	1000K	-1000K	0	1000K	1000K	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-33.51M	-35.92M	0	-50M	0	0	0	0	0
Other Financing	14.17M	25.46M	-13.05M	-101.2M	27.27M	2.99M	-85.38M	-85.79M	-31.46M	-42.39M
Net Change in Cash	11.29M	189.7M	-104.05M	-56.54M	211.71M	-61.88M	137.25M	30.6M	187.72M	368.84M
Free Cash Flow+	-376.22M	-207.98M	-124.41M	-96.76M	-52.15M	185.31M	54.94M	62.57M	475.42M	724.96M
FCF Margin %	-33.69%	-15.83%	-8.34%	-5.68%	-2.8%	10.04%	2.62%	2.59%	16.66%	-
FCF Growth %	16.27%	44.72%	40.18%	22.22%	46.1%	455.31%	-70.35%	13.88%	659.85%	52.49%
FCF per Share	-2.26	-1.19	-0.70	-0.54	-0.27	1.01	0.29	0.33	2.42	3.78
FCF Conversion (FCF/Net Income)	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x	30.91x
Interest Paid	8.64M	8.54M	11.62M	0	12.18M	10.39M	0	0	10.36M	0
Taxes Paid	95.86M	23.89M	16.68M	0	8.98M	18.15M	0	0	57.27M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-24.39%	-4.2%	-2.67%	-0.78%	23.63%	-1.53%	3.19%	3.51%	8.05%	0.46%
Return on Invested Capital (ROIC)	-21.12%	-0.34%	-2.77%	-2.2%	-0.81%	-1.33%	2.48%	2.71%	6.82%	-
Gross Margin	81.23%	81.59%	78.86%	78.91%	71.82%	74.52%	76%	78.01%	79.67%	-
Net Margin	-56.43%	-8.91%	-5.18%	-1.4%	45.9%	-3.47%	6.75%	6.93%	14.96%	-
Debt / Equity	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x	0.10x
Interest Coverage	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x	-
FCF Conversion	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x	30.91x
Revenue Growth	25.5%	17.62%	13.52%	14.27%	9.18%	-0.76%	13.53%	15.42%	17.97%	-100%

BioMarin Pharmaceutical Inc. (BMRN) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare BMRN vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

BioMarin Pharmaceutical Inc. (BMRN) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare BMRN vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios